bluebird bio (BLUE)

• Market cap: $36.5M
• 1 day: 0.54%
• 5 days: -4.58%
• 1 month: -48.42%
• 3 months: -51.98%
• 6 months: -67.53%
• Year to date: -56.85%
• 1 year: -85.90%
• 5 years: -99.54%
• 10 years: -99.85%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.

Employees: 375

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

731% more call options, than puts

Call options by funds: $40.7M | Put options by funds: $4.89M

3.15% less ownership

Funds ownership: 32.48% [Q3] → 29.33% (-3.15%) [Q4]

28% less capital invested

Capital invested by funds: $33M [Q3] → $23.7M (-$9.32M) [Q4]

42% less funds holding

Funds holding: 137 [Q3] → 80 (-57) [Q4]

77% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 71

95% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 61

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $5 33% upside
• Avg. target: $23 500% upside
• High target: $40 967% upside

2 analyst ratings

• positive: 1 50%
• neutral: 1 50%
• negative: 0 0%

Wells Fargo Yanan Zhu 7% 1-year accuracy 1 / 14 met price target	33% upside $5	Equal-Weight Maintained	24 Feb 2025
Barclays Gena Wang 17% 1-year accuracy 5 / 30 met price target	967% upside $40	Overweight Maintained	31 Dec 2024